Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 19, 2025, the company has repurchased a total of 906,265 ordinary fully paid securities, with an additional 130,000 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting confidence in its financial health and future growth prospects.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative biotherapies and influenza vaccines. The company is a global leader in the production of plasma-derived therapies and recombinant proteins, serving a wide range of medical needs across the world.
Average Trading Volume: 1,080,808
Technical Sentiment Signal: Sell
Current Market Cap: A$97.55B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.